Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
about
Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantationSecondary treatment of acute graft-versus-host disease: a critical reviewTreatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.Chronic graft-versus-host disease (GVHD) in children.Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD.Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.Chronic graft-versus-host disease: where is promise for the future?Biologic therapies for inflammatory eye disease.Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.Nonsurgical care of intestinal and multivisceral transplant recipients: a review for the intensivist.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.State-of-the-art acute and chronic GVHD treatment.The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients.Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.Daclizumab for children with corticosteroid refractory graft-versus-host disease.Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease
P2860
Q24240394-CC723370-A202-4400-BA92-951790D15704Q26823275-7F92D444-815C-4FD1-A28E-E8235ED9390EQ33213561-77FEB4E1-77C7-4EC4-BA98-5341B2C90DD1Q33857680-9925B7F3-F1CC-45F8-B198-0A3FDF1BAB9FQ34228345-6DF73860-9ADC-4E0E-B0F2-CD6953C107F5Q34441886-3CE7B7E4-9CB6-4465-89F6-0B70759FB880Q34703587-FE93853B-4771-444E-87F6-068130738441Q35745142-519D817D-61DE-4F25-9D71-F0A7F73176CBQ36113205-EC0ECFC7-7B1C-4CF1-9412-B9C987A7956BQ36180596-9A9FB246-C9D5-4867-82FE-9090C5896279Q36501675-DC8AA1D6-EBDA-421B-B93A-0F685E08B805Q37710227-5EAC8687-E26E-4D7B-93CC-6534D0CF4E23Q37810286-1D230CE0-6102-4715-94FD-722F1615F64FQ37851519-E6C28F89-800E-4801-A037-4DD33C79A256Q38021735-F09FC331-E2A5-4E47-8328-81D2E7CB840CQ38066586-896649BC-5D1B-49CE-A792-FDB9C0093EB5Q38416376-D8BAD461-8413-481C-AD0A-B73676788885Q38610904-1FA3EB9D-C187-4A96-9CD5-D883D2E44E1AQ39264020-786739BC-0FCD-4539-B0DF-E9BA59A52F9EQ46890995-3732330E-914C-405E-A147-C9FCC7ABF9AEQ50736148-693B0B02-C683-4A27-A39E-B8FC6155F495Q53652051-A178FF02-9C2F-4C19-A00F-5BD4B1B25F35Q53914683-E337AD77-5D14-4C02-A696-C502FCF717D0Q57252632-79FE853A-3C4A-4C54-A5F3-6A01546E313D
P2860
Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Improved survival in steroid-r ...... hensive infection prophylaxis.
@en
Improved survival in steroid-r ...... hensive infection prophylaxis.
@nl
type
label
Improved survival in steroid-r ...... hensive infection prophylaxis.
@en
Improved survival in steroid-r ...... hensive infection prophylaxis.
@nl
prefLabel
Improved survival in steroid-r ...... hensive infection prophylaxis.
@en
Improved survival in steroid-r ...... hensive infection prophylaxis.
@nl
P2093
P2860
P1476
Improved survival in steroid-r ...... hensive infection prophylaxis.
@en
P2093
Barrett AJ
Carvallo C
Chakrabarti S
Igarashi T
Srinivasan R
Takahashi Y
P2860
P304
P356
10.1111/J.1365-2141.2004.04856.X
P407
P577
2004-03-01T00:00:00Z